LOX-1+ PMN-MDSC enhances immune suppression which promotes glioblastoma multiforme progression

References

• Minniti G, De Sanctis V, Muni R, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma in elderly patients. J Neurooncol. 2008;88(1):97–103. doi:10.1007/s11060-008-9538-018250965
   PubMed Web of Science ®Google Scholar
• Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352(10):987–996. doi:10.1056/NEJMoa04333015758009
   PubMed Web of Science ®Google Scholar
• Poulsen HS, Urup T, Michaelsen SR, Staberg M, Villingshoj M, Lassen U. The impact of bevacizumab treatment on survival and quality of life in newly diagnosed glioblastoma patients. Cancer Manag Res. 2014;6:373–387. doi:10.2147/CMAR.S3930625298738
   PubMed Web of Science ®Google Scholar
• Ren Z, Liang J, Zhang P, Chen J, Wen J. Inhibition of human glioblastoma cell invasion involves PION@E6 mediated autophagy process. Cancer Manag Res. 2019;11:2643–2652. doi:10.2147/CMAR.S20015131015768
   PubMed Web of Science ®Google Scholar
• Syed M, Liermann J, Verma V, et al. Survival and recurrence patterns of multifocal glioblastoma after radiation therapy. Cancer Manag Res. 2018;10:4229–4235. doi:10.2147/CMAR.S16595630323678
   PubMed Web of Science ®Google Scholar
• Wang J, Liang H, Sun M, et al. Delta-6-desaturase inhibitor enhances radiation therapy in glioblastoma in vitro and in vivo. Cancer Manag Res. 2018;10:6779–6790. doi:10.2147/CMAR.S18560130584371
   PubMed Web of Science ®Google Scholar
• El Andaloussi A, Lesniak MS. CD4+ CD25+ FoxP3+ T-cell infiltration and heme oxygenase-1 expression correlate with tumor grade in human gliomas. J Neurooncol. 2007;83(2):145–152. doi:10.1007/s11060-006-9314-y17216339
   PubMed Web of Science ®Google Scholar
• Perng P, Lim M. Immunosuppressive mechanisms of malignant gliomas: parallels at non-CNS sites. Front Oncol. 2015;5:153. doi:10.3389/fonc.2015.0015326217588
   PubMed Web of Science ®Google Scholar
• Crane CA, Ahn BJ, Han SJ, Parsa AT. Soluble factors secreted by glioblastoma cell lines facilitate recruitment, survival, and expansion of regulatory T cells: implications for immunotherapy. Neuro-oncology. 2012;14(5):584–595. doi:10.1093/neuonc/nos01422406925
   PubMed Web of Science ®Google Scholar
• Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646–674. doi:10.1016/j.cell.2011.02.01321376230
   PubMed Web of Science ®Google Scholar
• Condamine T, Ramachandran I, Youn JI, Gabrilovich DI. Regulation of tumor metastasis by myeloid-derived suppressor cells. Annu Rev Med. 2015;66:97–110. doi:10.1146/annurev-med-051013-05230425341012
   PubMed Web of Science ®Google Scholar
• Khaled YS, Ammori BJ, Elkord E. Myeloid-derived suppressor cells in cancer: recent progress and prospects. Immunol Cell Biol. 2013;91(8):493–502. doi:10.1038/icb.2013.2923797066
   PubMed Web of Science ®Google Scholar
• Messmer MN, Netherby CS, Banik D, Abrams SI. Tumor-induced myeloid dysfunction and its implications for cancer immunotherapy. Cancer Immunol Immunother. 2015;64(1):1–13. doi:10.1007/s00262-014-1639-325432147
   PubMed Web of Science ®Google Scholar
• Wang PF, Song SY, Wang TJ, et al. Prognostic role of pretreatment circulating MDSCs in patients with solid malignancies: A meta-analysis of 40 studies. Oncoimmunology. 2018;7(10):e1494113. doi:10.1080/2162402X.2018.149085430288362
   PubMed Web of Science ®Google Scholar
• Youn JI, Nagaraj S, Collazo M, Gabrilovich DI. Subsets of myeloid-derived suppressor cells in tumor-bearing mice. J Immunol. 2008;181(8):5791–5802. doi:10.4049/jimmunol.181.8.579118832739
   PubMed Web of Science ®Google Scholar
• Poschke I, Kiessling R. On the armament and appearances of human myeloid-derived suppressor cells. Clin Immunol. 2012;144(3):250–268. doi:10.1016/j.clim.2012.06.00322858650
   PubMed Web of Science ®Google Scholar
• Barrera L, Montes-Servin E, Hernandez-Martinez JM, et al. Levels of peripheral blood polymorphonuclear myeloid-derived suppressor cells and selected cytokines are potentially prognostic of disease progression for patients with non-small cell lung cancer. Cancer Immunol Immunother. 2018;67(9):1393–1406. doi:10.1007/s00262-018-2196-y29974189
   PubMed Web of Science ®Google Scholar
• Romano A, Parrinello NL, La Cava P, et al. PMN-MDSC and arginase are increased in myeloma and may contribute to resistance to therapy. Expert Rev Mol Diagn. 2018;18(7):675–683. doi:10.1080/14737159.2018.147092929707981
   PubMed Web of Science ®Google Scholar
• Condamine T, Dominguez GA, Youn JI, et al. Lectin-type oxidized LDL receptor-1 distinguishes population of human polymorphonuclear myeloid-derived suppressor cells in cancer patients. Sci Immunol. 2016;1:2. doi:10.1126/sciimmunol.aah6817
   Web of Science ®Google Scholar
• Serafini P, Borrello I, Bronte V. Myeloid suppressor cells in cancer: recruitment, phenotype, properties, and mechanisms of immune suppression. Semin Cancer Biol. 2006;16(1):53–65. doi:10.1016/j.semcancer.2005.07.00516168663
   PubMed Web of Science ®Google Scholar
• Millrud CR, Bergenfelz C, Leandersson K. On the origin of myeloid-derived suppressor cells. Oncotarget. 2017;8(2):3649–3665. doi:10.18632/oncotarget.1227827690299
   PubMedGoogle Scholar
• Raychaudhuri B, Rayman P, Ireland J, et al. Myeloid-derived suppressor cell accumulation and function in patients with newly diagnosed glioblastoma. Neuro-oncology. 2011;13(6):591–599. doi:10.1093/neuonc/nor04221636707
   PubMed Web of Science ®Google Scholar
• Greten TF, Manns MP, Korangy F. Myeloid derived suppressor cells in human diseases. Int Immunopharmacol. 2011;11(7):802–807. doi:10.1016/j.intimp.2011.01.00321237299
   PubMed Web of Science ®Google Scholar
• Kong YY, Fuchsberger M, Xiang SD, Apostolopoulos V, Plebanski M. Myeloid derived suppressor cells and their role in diseases. Curr Med Chem. 2013;20(11):1437–1444.23409714
   PubMed Web of Science ®Google Scholar
• Solito S, Falisi E, Diaz-Montero CM, et al. A human promyelocytic-like population is responsible for the immune suppression mediated by myeloid-derived suppressor cells. Blood. 2011;118(8):2254–2265. doi:10.1182/blood-2010-12-32575321734236
   PubMed Web of Science ®Google Scholar
• Heimberger AB, Abou-Ghazal M, Reina-Ortiz C, et al. Incidence and prognostic impact of FoxP3+ regulatory T cells in human gliomas. Clin Cancer Res. 2008;14(16):5166–5172. doi:10.1158/1078-0432.CCR-08-032018698034
   PubMed Web of Science ®Google Scholar
• Fecci PE, Mitchell DA, Whitesides JF, et al. Increased regulatory T-cell fraction amidst a diminished CD4 compartment explains cellular immune defects in patients with malignant glioma. Cancer Res. 2006;66(6):3294–3302. doi:10.1158/0008-5472.CAN-05-377316540683
   PubMed Web of Science ®Google Scholar
• Fujita M, Kohanbash G, Fellows-Mayle W, et al. COX-2 blockade suppresses gliomagenesis by inhibiting myeloid-derived suppressor cells. Cancer Res. 2011;71(7):2664–2674. doi:10.1158/0008-5472.CAN-10-305521324923
   PubMed Web of Science ®Google Scholar
• Chen Z, Xu N, Zhao C, Xue T, Wu X, Wang Z. Bevacizumab combined with chemotherapy vs single-agent therapy in recurrent glioblastoma: evidence from randomized controlled trials. Cancer Manag Res. 2018;10:2193–2205. doi:10.2147/CMAR.S17332330087578
   PubMed Web of Science ®Google Scholar
• Hatoum A, Mohammed R, Zakieh O. The unique invasiveness of glioblastoma and possible drug targets on extracellular matrix. Cancer Manag Res. 2019;11:1843–1855.30881112
   PubMed Web of Science ®Google Scholar
• O’Donnell JS, Hoefsmit EP, Smyth MJ, Blank CU, Teng MWL. The promise of neoadjuvant immunotherapy and surgery for cancer treatment. Clin Cancer Res. 2019. doi:10.1158/1078-0432.CCR-18-2641
   PubMed Web of Science ®Google Scholar